Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit - Schedule of Warrant Activity (Details)

v3.21.1
Stockholders' Deficit - Schedule of Warrant Activity (Details)
 9 Months Ended
Mar. 31, 2021
USD ($)
$ / shares
shares
Equity [Abstract]  
Number of Shares, Outstanding, Beginning balance | shares 151,170
Number of Shares, Issued | shares
Number of Shares, Exercised | shares (23,575)
Number of Shares, Forfeited | shares
Number of Shares, Expired | shares
Number of Shares, Outstanding, Ending balance | shares 127,595
Number of Shares, Exercisable, Ending balance | shares 79,971 [1]
Weighted Average Price Per Share, Outstanding, Beginning balance | $ / shares $ 150.00
Weighted Average Price Per Share, Issued | $ / shares
Weighted Average Price Per Share, Exercised | $ / shares 22.36
Weighted Average Price Per Share, Forfeited | $ / shares
Weighted Average Price Per Share, Expired | $ / shares
Weighted Average Price Per Share, Outstanding, Ending balance | $ / shares 172.80
Weighted Average Price Per Share, Exercisable, Ending balance | $ / shares $ 286.44 [1]
Weighted average remaining contractual term 2 years 7 days
Aggregate intrinsic value | $ $ 0
[1] Series C warrants shall be exercisable ratably upon exercise of Series B warrants.